RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

• click to rate

  Posted by Two Blokes Jul 10 - Filed in Stock - 4 views
  
  Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.